T1	intervention 30 36	APF530
T2	control 44 56	palonosetron
T3	condition 78 118	chemotherapy-induced nausea and vomiting
T5	eligibility 134 216	patients with breast cancer receiving moderately or highly emetogenic chemotherapy
T6	total-participants 1031 1034	423
T7	total-participants 1044 1047	185
T8	outcome 1191 1215	CRs in cycle 1 for acute
T9	iv-bin-percent 1236 1240	71 %
T10	iv-bin-percent 1246 1250	77 %
T11	iv-bin-percent 1264 1268	73 %
T12	iv-bin-percent 1274 1278	73 %
T13	cv-bin-percent 1408 1412	52 %
T14	cv-bin-percent 1418 1422	52 %
T15	outcome 1424 1428	CINV
T17	cv-bin-percent 1298 1302	68 %
T18	cv-bin-percent 1308 1312	66 %
T19	outcome 1318 1325	delayed
T20	iv-bin-percent 1346 1350	46 %
T21	iv-bin-percent 1356 1360	58 %
T22	iv-bin-percent 1374 1378	48 %
T23	iv-bin-percent 1384 1388	63 %
T4	outcome-Measure 930 947	complete response
